Skip to main navigation Skip to search Skip to main content

Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial

  • Nicola G. Ghazi
  • , Emad B. Abboud
  • , Sawsan R. Nowilaty
  • , Hisham Alkuraya
  • , Abdulrahman Alhommadi
  • , Huimin Cai
  • , Rui Hou
  • , Wen Tao Deng
  • , Sanford L. Boye
  • , Abdulrahman Almaghamsi
  • , Fahad Al Saikhan
  • , Hassan Al-Dhibi
  • , David Birch
  • , Christopher Chung
  • , Dilek Colak
  • , Matthew M. LaVail
  • , Douglas Vollrath
  • , Kirsten Erger
  • , Wenqiu Wang
  • , Thomas Conlon
    • Kang Zhang, William Hauswirth, Fowzan S. Alkuraya
  • King Khaled Eye Specialist Hospital
  • University of Virginia
  • Al-Imam Muhammad Ibn Saud Islamic University
  • University of California at San Diego
  • Chengdu JiaChuan Biomedicine Co., Ltd
  • Guangzhou KangRui Biological Pharmaceutical Technology Company Ltd.
  • University of Florida
  • Retina Foundation of the Southwest
  • King Faisal Specialist Hospital and Research Centre
  • University of California at San Francisco
  • Stanford University
  • Department of Veterans Affairs
  • Alfaisal University

Research output: Contribution to journal › Article › peer-review

240 Scopus citations

Fingerprint

Dive into the research topics of 'Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology

Neuroscience

Pharmacology, Toxicology and Pharmaceutical Science